New and improved production method for glucosamine developed by Øyvind Brekke at the University NTNU in Norway (the Brekke-method).
Glucomed AS established as holding company for the development, production and sales of glucosamine ingredient and finished products.
Co-operation established with the Norwegian pharmaceutical company Weifa AS for the development of a glucosamine pharmaceutical product. Co-operation established with Hydro Organic for further development of the Brekke-method. External investors invited in as shareholders. All placements fully subscribed.
Application for Marketing Authorization for the finished product Glucomed filed in Sweden. First marketing and distribution agreement for Glucomed signed with Meda AB. Change of name to Navamedic ASA
Marketing Authorization received for Glucomed in Sweden. MRP application launched. Glucomed launched in Sweden.
Approval of Glucomed in 24 further EU/EEA countries through the decision in the EU Commission. Started construction of chitin plant adjasent to Nergård Reker at Senjahopen, Troms. Glucomed launched on Iceland. The Navamedic share listed on Oslo Stock Exchange.
Acquisition of Vitaflo Scandinavia AB. Glucomed launched in Germany, United Kingdom, Denmark, the Czech Republic, the Slovak Republic and Austria.
Integration of Vitaflo in the Group and sale of the Glucomed business area.
Restruction with new management.
Exclusive distribution agreement with Aspen Pharma
Introducing the first generic products